Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice

Leukemia

Volumn 30, Issue 1, 2016, Pages 190-199

  Etchin, J ^a,b   Montero, J ^a   Berezovskaya, A ^a   Le, B T ^a   Kentsis, A ^c   Christie, A L ^a   Conway, A S ^a   Chen, W C ^d,e   Reed, C ^a   Mansour, M R ^a,f   Ng, C E L ^a   Adamia, S ^a   Rodig, S J ^g   Galinsky, I A ^a   Stone, R M ^a   Klebanov, B ^h   Landesman, Y ^h   Kauffman, M ^h   Shacham, S ^h   Kung, A L ⁱ   Wang, J C Y ^d,e   Letai, A ^a   Look, A T ^a,b   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h Karyopharm Therapeutics   (United States)

ⁱ Medical Center ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; CD45 ANTIGEN; EXPORTIN 1; MESSENGER RNA; SELINEXOR; CELL RECEPTOR; EXPORTIN 1 PROTEIN; HYDRAZINE DERIVATIVE; KARYOPHERIN; KPT-330; TRIAZOLE DERIVATIVE;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CELL PROLIFERATION; CELL SELF-RENEWAL; CONTROLLED STUDY; CYTOTOXICITY; EX VIVO STUDY; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; KARYOTYPE; LEUKEMIA CELL; LEUKEMIA INITIATING CELL; LEUKOCYTE COUNT; MOUSE; NONHUMAN; NUCLEAR EXPORT SIGNAL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SPLEEN WEIGHT; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER STEM CELL; DRUG EFFECTS; DRUG SCREENING; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA, MYELOID, ACUTE; PATHOLOGY;

ANIMALS; HUMANS; HYDRAZINES; IMMUNOSUPPRESSION; KARYOPHERINS; LEUKEMIA, MYELOID, ACUTE; MICE; NEOPLASTIC STEM CELLS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84953352221     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.194     Document Type: Article

References (42)

1. Estey EH. Acute myeloid leukemia: 2014 update on risk-stratification and management. Am J Hematol 2014; 89: 1063-1081.
2. Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012; 366: 1079-1089.
3. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-737.
4. Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 2004; 5: 738-743.
5. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645-648.
6. Gilliland DG, Jordan CT, Felix CA. The molecular basis of leukemia. Hematology Am Soc Hematol Educ Program 2004: 80-97.
7. Fornerod M, Ohno M, Yoshida M, Mattaj IW. CRM1 is an export receptor for leucine-rich nuclear export signals. Cell 1997; 90: 1051-1060.
8. Fukuda M, Asano S, Nakamura T, Adachi M, Yoshida M. CRM1 is responsible for intracellular transport meditted by the nuclear export signal. Nature 1997; 390: 308-311.
9. Ossareh-Nazari B, Bachelerie F, Dargemont C. Evidence for a role of CRM1 in signal-mediated nuclear protein export. Science 1997; 278: 141-144.
10. Turner JG, Dawson J, Sullivan DM. Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol 2012; 83: 1021-1032.
11. Stade K, Ford CS, Guthrie C, Weis K. Exportin 1 (Crm1p) is an essential nuclear export factor. Cell 1997; 90: 1041-1050.
12. Culjkovic B, Topisirovic I, Skrabanek L, Ruiz-Gutierrez M, Borden KL. eIF4E is a central node of an RNA regulon that governs cellular proliferation. J Cell Biol 2006; 175: 415-426.
13. Xu D, Farmer A, Chook YM. Recognition of nuclear targeting signals by Karyopherin-beta proteins. Curr Opin Struct Biol 2010; 20: 782-790.
14. Dong X, Biswas A, Chook YM. Structural basis of assembly and disassembly of the CRM1 nuclear export complex. Nat Struct Mol Biol 2009; 16: 558-560.
15. Dong X, Biswas A, Suel KE, Jackson LK, Martinez R, Gu H et al. Structural basis for leucine-rich nuclear export signal recognition by CRM1. Nature 2009; 458: 1136-1141.
16. Guttler T, Gorlich D. Ran-dependent nuclear export mediators: a structural perspective. EMBO J 2011; 30: 3457-3474.
17. Hutten S, Kehlenbach RH. CRM1-mediated nuclear export: to the pore and beyond. Trends Cell Biol 2007; 17: 193-201.
18. Koyama M, Matsuura Y. An allosteric mechanism to displace nuclear export cargo from CRM1 and RanGTP by RanBP1. EMBO J 2010; 29: 2002-2013.
19. Xu D, Farmer A, Collett G, Grishin NV, Chook YM. Sequence and structural analyses of nuclear export signals in the NESdb database. Mol Biol Cell 2012; 23: 3677-3693.
20. Xu D, Grishin NV, Chook YM. NESdb: a database of NES-containing CRM1 cargos. Mol Biol Cell 2012; 23: 3673-3676.
21. Kojima K, Kornblau SM, Ruvolo V, Dilip A, Duvvuri S, Davis RE et al. Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood 2013; 121: 4166-4174.
22. Lapalombella R, Sun Q, Williams K, Tangeman L, Jha S, Zhong Y et al. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood 2012; 120: 4621-4634.
23. Huang WY, Yue L, Qiu WS, Wang LW, Zhou XH, Sun YJ. Prognostic value of CRM1 in pancreas cancer. Clin Invest Med 2009; 32: E315.
24. Inoue H, Kauffman M, Shacham S, Landesman Y, Yang J, Evans CP et al. CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth. J Urol 2013; 189: 2317-2326.
25. Shen A, Wang Y, Zhao Y, Zou L, Sun L, Cheng C. Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis. Neurosurgery 2009; 65: 153-159, discussion 159-160.
26. Walker CJ, Oaks JJ, Santhanam R, Neviani P, Harb JG, Ferenchak G et al. Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. Blood 2013; 122: 3034-3044.
27. Yao Y, Dong Y, Lin F, Zhao H, Shen Z, Chen P et al. The expression of CRM1 is associated with prognosis in human osteosarcoma. Oncol Rep 2009; 21: 229-235.
28. Etchin J, Sanda T, Mansour MR, Kentsis A, Montero J, Le BT et al. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br J Haematol 2013; 161: 117-127.
29. Kalid O, Toledo Warshaviak D, Shechter S, Sherman W, Shacham S. Consensus Induced Fit Docking (cIFD): methodology, validation, and application to the discovery of novel Crm1 inhibitors. J Comput Aided Mol Des 2012; 26: 1217-1228.
30. Etchin J, Sun Q, Kentsis A, Farmer A, Zhang ZC, Sanda T et al. Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells. Leukemia 2013; 27: 66-74.
31. Savona M, Garzon R, de Nully Brown P, Yee K, Lancet JE, Gutierrez M et al. Phase I trial of selinexor (KPT-330), a first-in-class oral selective inhibitor of nuclear export (SINE) in patients (pts) with advanced acute myelogenous leukemia (AML). Blood 2013; 122.
32. Ranganathan P, Yu X, Na C, Santhanam R, Shacham S, Kauffman M et al. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood 2012; 120: 1765-1773.
33. Schmidt J, Braggio E, Kortuem KM, Egan JB, Zhu YX, Xin CS et al. Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276. Leukemia 2013; 27: 2357-2365.
34. Tai YT, Landesman Y, Acharya C, Calle Y, Zhong MY, Cea M et al. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia 2014; 28: 155-165.
35. Sarry JE, Murphy K, Perry R, Sanchez PV, Secreto A, Keefer C et al. Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rgammac-deficient mice. J Clin Invest 2011; 121: 384-395.
36. Ryan J, Letai A. BH3 profiling in whole cells by fluorimeter or FACS. Methods 2013; 61: 156-164.
37. Ryan JA, Brunelle JK, Letai A. Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes. Proc Natl Acad Sci USA 2010; 107: 12895-12900.
38. Hu Y, Smyth GK. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods 2009; 347: 70-78.
39. Borrow J, Stanton Jr VP, Andresen JM, Becher R, Behm FG, Chaganti RS et al. The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet 1996; 14: 33-41.
40. Yosef Landesman WS, Jean-Richard S-M, Trinayan K, Louis P, Vincent S, Sharon S et al. Abstract 3775: Pharmacokinetic (PK)/pharmacodynamic (PD) and efficacy relationship of selective inhibitors of nuclear export (KPT-SINE). Cancer Res 2012; 72: 3775.
41. Del Gaizo Moore V, Letai A. BH3 profiling-measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions. Cancer Lett 2013; 332: 202-205.
42. Montero J, Sarosiek KA, DeAngelo JD, Maertens O, Ryan J, Ercan D et al. Druginduced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell 2015; 160: 977-989.